FDA Approves Additional Recommended Dose of Pembrolizumab in Adults

The FDA approved an additional recommended dose of 400 mg pembrolizumab (Keytruda)  every 6 weeks across all adult indications.

Source: CancerNetwork - April 28, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news